Literature DB >> 3938008

Peripherally inserted central venous catheters for treatment of cystic fibrosis.

R L Zanni, J G Shutack, P M Schuler, D Christie, D S Holsclaw.   

Abstract

Patients who have cystic fibrosis (CF) are frequently hospitalized for long-term intravenous (IV) treatment. We evaluated clinical effectiveness of the Drum-Cartridge Catheter (Abbott Laboratories) for such patients. The catheter is placed peripherally under local anesthesia via an antecubital vein into the superior vena cava or right atrium. Patients who were more than 10 years of age and who were hospitalized for IV antibiotic therapy and/or IV hyperalimentation were studied. All but 2 patients had CF. Using an aseptic technique the catheters were inserted into the basilic or cephalic vein. Chest radiographs were used to confirm the final location of the catheter. Catheters were used to administer IV antibiotics, hyperalimentation, and lipids. There were 38 catheterizations in 23 patients; several patients had repeated insertions at later admissions. The success rate of insertion was 86% with 31 of the 38 insertions initially located either in the superior vena cava or right atrium. Mean duration of catheterization was 15.4 days (range 5-49 days). No major complications such as sepsis, catheter or clot embolism, pneumothorax, vascular perforation, or hemorrhage occurred in the patients who had DF. Complications that required displacement of catheter into the axillary vein (1 patient), and cracked catheter hub (1 patient). This study shows that the Drum-Cartridge Catheter can be used easily for IV therapy of patients who have CF for a long duration, repeatedly, and with no major complications.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3938008     DOI: 10.1002/ppul.1950010611

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  1 in total

1.  Peripherally inserted central catheter placement in cancer patients with profound thrombocytopaenia: a prospective analysis.

Authors:  Julien Potet; Alphonse Thome; Emmanuel Curis; François-Xavier Arnaud; Gabrielle Weber-Donat; Laura Valbousquet; Evelyne Peroux; Eric Flor; Christophe Dody; Johanna Konopacki; Jean Valère Malfuson; Cecile Cartry; Marion Lahutte; Thierry de Revel; Jacques Baccialone; Christophe A Teriitehau
Journal:  Eur Radiol       Date:  2013-02-26       Impact factor: 5.315

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.